CapVest recapitalises Curium in $7bn record deal targeting accelerated growth
Curium, a leading producer of radiopharmaceuticals, and global investment firm CapVest Partners (CapVest) have announced the recapitalisation of Curium via a new Continuation Vehicle (CV) that values Curium at circa $7bn, making this the largest transaction in nuclear medicine globally. The transaction elicited wide support from existing and new institutional investors across the US, Europe, the Middle East and APAC.…
Spanish competition agency vetoes “competition threatening” radiopharma deal
Spain’s competition agency (CNMC) has prohibited Curium Pharma Holding Spain (Curium), a global leader in nuclear medicine, from acquiring Institut de Radiofarmacia Aplicada de Barcelona (IRAB). It said on Monday, October 6 that the merger poses an obstacle to effective competition in the markets for PET radiopharmaceuticals which are used in cancer detection tests, and contract manufacturing services to third…